Compare BMEA & TLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | TLYS |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.6M | 128.1M |
| IPO Year | 2021 | 2011 |
| Metric | BMEA | TLYS |
|---|---|---|
| Price | $1.25 | $4.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.83 | $2.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 05-12-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | 62.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.66 |
| Revenue Next Year | N/A | $1.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.14 |
| 52 Week High | $2.99 | $6.25 |
| Indicator | BMEA | TLYS |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 59.17 |
| Support Level | $1.17 | $3.68 |
| Resistance Level | $1.47 | $4.96 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 0.00 | 73.33 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley, among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.